Varón de 57 años con lesión interdigital en el pie izquierdo
- Rodríguez López, C. 1
- Curiel García, T. 1
- Mateos González, M. 1
- Pumares Pérez, J. 1
- 1 Servicio de Oncología Médica y Grupo de Oncología Médica Traslacional, Hospital Clínico Universitario e Instituto de Investigación Sanitaria-CIBERON, Santiago de Compostela, La Coruña, España
ISSN: 0304-5412
Year of publication: 2021
Issue Title: Enfermedades oncológicas (IV)Melanoma, cáncer de mama y tumores ginecológicos
Series: 13
Issue: 27
Pages: 1546-1547
Type: Article
More publications in: Medicine: Programa de Formación Médica Continuada Acreditado
Bibliographic References
- Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Departament of Health and Human Services. National Institutes of Health. National Cancer Institute
- Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600) mutant melanoma (coBRIM): updated efficacy results from a randomised, double blind, phase 3 trial. Lancet Oncol. 2016;17:1248-60.
- Larkin J, Minor D, D ́Angelo S, Neyns B, Smylie M, Miller WH Jr, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator`s choice chemotherapy in CheckMate 037: a randomized, controlled, open label phase III trial. J Clin Oncol. 2018;36:383-90.
- Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, et al. Vemurafenib in patients with BRAFV600 mutation positive metastasic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;28:2581-7.
- Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF mutant melanoma: a multicentre, double blind, phase 3 randomised controlled trial. Lancet. 2015;386:444-51.
- Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-32.